Literature DB >> 7436584

Hepatitis B virus and polymyalgia rheumatica: a search for HBsAg, HBsAb, HBcAb, HBeAg, and HBeAb.

H Elling, P Skinhøj, P Elling.   

Abstract

Forty-three consecutive patients with polymyalgia rheumatica were studied for serological markers of actual or previous hepatitis B virus infection. Signs of active virus replication, which include HBsAg supported by the presence of HBeAg and anti-HBc in high titres, were not found in any cases. Anti-HBs, a serological sign of previous hepatitis B virus exposure, was present in 16.8%. The prevalence of anti-HBs is strongly age-dependent in the normal population, and its prevalence in polymyalgia rheumatica was not significantly different from the incidence found in other hospital patients. No significantly raised incidence was found in any subgroups, including patients without liver dysfunction. These results do not support the concept that current or previous hepatitis B virus infection plays any role in the pathogenesis of the majority of cases of polymyalgia rheumatica.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436584      PMCID: PMC1000595          DOI: 10.1136/ard.39.5.511

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  [Vasculitis in hepatitis B infection].

Authors:  J Müller-Schoop; N Gerber; M Knoblauch
Journal:  Schweiz Med Wochenschr       Date:  1977-04-16

2.  Association between hepatitis B virus and essential mixed cryoglobulinemia.

Authors:  Y Levo; P D Gorevic; H J Kassab; D Zucker-Franklin; E C Franklin
Journal:  N Engl J Med       Date:  1977-06-30       Impact factor: 91.245

3.  Hepatitis associated antigen and periarteritis nodosa (PAN).

Authors:  C Trepo; J Thivolet
Journal:  Vox Sang       Date:  1970 Sep-Oct       Impact factor: 2.144

4.  Incidence and meaning of the "e" determinant among hepatitis-B-antigen positive patients with acute and chronic liver diseases. Report from the Copenhagen Hepatitis Acuta Programme.

Authors:  J O Nielsen; O Dietrichson; E Juhl
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

5.  Systemic giant-cell arteritis with polymyalgia rheumatica, reversible abnormalities of liver function.

Authors:  E R Dickson; J E Maldonado; S G Sheps; J A Cain
Journal:  JAMA       Date:  1973-06-11       Impact factor: 56.272

6.  Preparation and characterization of hepatitis B-antigen for radioimmunoassay.

Authors:  P Skinhöj; J F Hansen
Journal:  Scand J Clin Lab Invest       Date:  1973-11       Impact factor: 1.713

7.  Hepatitis-associated antigen. Qualitative and quantitative determination.

Authors:  P Skinhöj; H Thulstrup
Journal:  Scand J Clin Lab Invest       Date:  1971-02       Impact factor: 1.713

8.  Association between polyarteritis and Australia antigen.

Authors:  D J Gocke; K Hsu; C Morgan; S Bombardieri; M Lockshin; C L Christian
Journal:  Lancet       Date:  1970-12-05       Impact factor: 79.321

9.  Hepatitis-B antibody in polymyalgia Rheumatica.

Authors:  P A Bacon; S M Doherty; A J Zuckerman
Journal:  Lancet       Date:  1975-09-13       Impact factor: 79.321

10.  Age- and sex-related distribution of antibodies to hepatitis B surface and core antigens in a Swedish population.

Authors:  B G Hansson
Journal:  Acta Pathol Microbiol Scand B       Date:  1976-12
View more
  4 in total

1.  Polymyalgic presentation of enterovirus infection: a cause of diagnostic confusion.

Authors:  R J Stevens; R A Hughes
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

Review 2.  Clinical associations between arthritis and liver disease.

Authors:  P R Mills; R D Sturrock
Journal:  Ann Rheum Dis       Date:  1982-06       Impact factor: 19.103

Review 3.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

4.  Hepatitis B virus infection in patients with rheumatic diseases.

Authors:  H Permin; J Aldershvile; J O Nielsen
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.